Point mutation increases a form of the NK1 receptor with high affinity for neurokinin A and B and septide

Open Access
Publisher Website
Google Scholar
Abstract
1 The binding modalities of substance P and neurokinin A on the wild type and Gly166 to‐Cys mutant NK1 receptors expressed on CHO cells were investigated in homologous and heterologous binding experiments using both radiolabelled substance P and neurokinin A. 2 On the wild type NK1 receptor NKA displaces radiolabelled substance P with very low apparent affinity, despite its high‐affinity binding constant (determined in homologous binding experiments). The Gly166 to‐Cys substitution in the NK1 tachykinin receptor greatly enhances the apparent affinity of neurokinin A in competition for radiolabelled substance P, but it does not change the binding constant of neurokinin A. The mutation, thereby, eliminates the discrepancy between the low apparent affinity and the high binding constant of neurokinin A. 3 On the wild type receptor the binding capacity of neurokinin A is significantly smaller than that of substance P. In contrast, the two tachykinins bind to approximately the same number of sites on the mutant receptor. 4 Simultaneous mass action law analysis of binding data in which multiple radioligands were employed in parallel demonstrated that a one‐site model was unable to accommodate all the experimental data, whereas a two‐site model provided a dramatically better description. 5 These two receptor‐sites display equally high affinity for substance P, while neurokinin A strongly discriminates between a high and a low affinity component. The binding affinities of neurokinin A are not affected by the mutation, which instead specifically alters the distribution between receptor sites in favour of a high affinity neurokinin A binding form. 6 The low apparent affinity and binding capacity of neurokinin A on the wild type receptor results from neurokinin A binding with high affinity only to a fraction of the sites labelled by substance P. The mutation increases the proportion of this site, and consequently enhances the apparent affinity and binding capacity of neurokinin A. 7 The binding modalities of septide‐like ligands (i.e. neurokinin B, SP(6–11), SP‐methyl ester) are affected similarly to neurokinin A and are better resolved into two sites. The mutation leaves the affinity of these ligands for the two receptor forms unchanged, but increases the fraction of high‐affinity sites. On the other hand, the binding of non‐peptide and peptide antagonists (SR140.333 and FK888) behaved similarly to substance P with a single high affinity site that is unaffected by the mutation. 8 These findings may suggest that the NK1 receptor exists in two different forms with similar affinity for substance P and NK1 antagonists, but with a high and a low affinity for neurokinin A and septide‐like ligands. Hence, the Gly166 in the NK1 receptor would seem to control the distribution between a pan‐reactive form and a substance P‐selective form of the receptor. British Journal of Pharmacology (1998) 125, 393–401; doi:10.1038/sj.bjp.0702070